Clinical Trial: NCT05740943
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Guangdong Provincial People's Hospital |
| Information Provided By: | Guangdong Provincial People's Hospital |
| Last Update Posted: | 2026-01-20 |
Study Overview
Brief Summary
A prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical feasibility of dynamic ctDNA and multidisciplinary assessment in guiding local treatments.
Official Title
Induction Lorlatinib for ALK Fusion Locally Advanced Non-small Cell Lung Cancer: A Prospective, Single Arm, Open-label Phase 2 Study
Conditions
Stage III NSCLC, Surgery
Intervention / Treatment
- Drug: Lorlatinib
Other Study ID Numbers
- LORIN
Start Date (Actual)
2023-03-15
Primary Completion Date (Actual)
2025-12-31
Study Completion Date (Estimated)
2026-04-30
Enrollment (Estimated)
48
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Guangdong Provincial People's Hospital |
| Information Provided By: | Guangdong Provincial People's Hospital |
| Last Update Posted: | 2026-01-20 |
Study Overview
Brief Summary
A prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical feasibility of dynamic ctDNA and multidisciplinary assessment in guiding local treatments.
Official Title
Induction Lorlatinib for ALK Fusion Locally Advanced Non-small Cell Lung Cancer: A Prospective, Single Arm, Open-label Phase 2 Study
Conditions
Stage III NSCLC, Surgery
Intervention / Treatment
- Drug: Lorlatinib
Other Study ID Numbers
- LORIN
Start Date (Actual)
2023-03-15
Primary Completion Date (Actual)
2025-12-31
Study Completion Date (Estimated)
2026-04-30
Enrollment (Estimated)
48
Study Type
Interventional
Phase
Phase 2